.Attribute Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical consequence of 11 months, clients along with metastatic stomach lumps who acquired biomarker-matched therapies based on circulating growth DNA profiling revealed a greater clinical perk than those acquiring unmatched therapy.